We aim to evaluate 3-year effects of ocrelizumab (humanized anti-CD20 monoclonal antibody for the treatment of multiple sclerosis (MS)) on lymphocytes, neutrophils and immunoglobulins: (1) when compared with pre-infusion assessment; (2) over the course of treatment; and (3) possible clinical correlates of the observed immunological modifications.
Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study / Capasso, Nicola; Palladino, Raffaele; Cerbone, Vincenza; Spiezia, Antonio Luca; Covelli, Bianca; Fiore, Antonia; Lanzillo, Roberta; Carotenuto, Antonio; Petracca, Maria; Stanziola, Lucia; Scalia, Giulia; Brescia Morra, Vincenzo; Moccia, Marcello. - In: JOURNAL OF NEUROLOGY. - ISSN 1432-1459. - (2022). [10.1007/s00415-022-11350-1]
Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study
Capasso, Nicola;Palladino, Raffaele;Cerbone, Vincenza;Spiezia, Antonio Luca;Covelli, Bianca;Fiore, Antonia;Lanzillo, Roberta;Carotenuto, Antonio;Petracca, Maria;Scalia, Giulia;Brescia Morra, Vincenzo;Moccia, Marcello
2022
Abstract
We aim to evaluate 3-year effects of ocrelizumab (humanized anti-CD20 monoclonal antibody for the treatment of multiple sclerosis (MS)) on lymphocytes, neutrophils and immunoglobulins: (1) when compared with pre-infusion assessment; (2) over the course of treatment; and (3) possible clinical correlates of the observed immunological modifications.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
